Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression
Tomoyuki Nakamura, Masaru Tomita, N. Horikawa, M. Ishibashi, K. Uematsu, T. Hiraki, T. Abe, N. Uchimura
Neuropsychopharmacology Reports February 21, 2021 DOI: 10.1002/npr2.12165 via Semantic Scholar
Summary
About one-third of patients with major depressive disorder have treatment-resistant depression. Of those, one-third do not respond to ketamine, a newer antidepressant. Resting-state functional MRI was tested for its ability to predict which patients with treatment-resistant depression would respond to ketamine treatment.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Keywords | Medicine Psychology |
| Citations | 29 |
| Key finding | Resting-state functional MRI may help predict treatment response to ketamine in treatment-resistant depression. |
Abstract
Approximately one‐third of patients with major depressive disorder develop treatment‐resistant depression. One‐third of patients with treatment‐resistant depression demonstrate resistance to ketamine, which is a novel antidepressant effective for this disorder. The objective of this study was to examine the utility of resting‐state functional magnetic resonance imaging for the prediction of treatment response to ketamine in treatment‐resistant depression.